PTO does not appear to invalidate very many gene patent method claims (Holman’s Biotech IP Blog) US: Machine-or-transformation test after Myriad: Implications to the prosecution of process claims (Patent Law Practice Center) US: Unsuccessful Qui Tam plaintiff asserting false marking claim not immune from costs award: Promote Innovation v Roche Diagnostics (Docket Report) US: FDA releases two medical device draft guidances (FDA Law Blog) US: BIO: Unleashing the promise of biotechnology… [read post]